First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small Cell Lung Cancer
EGFR Mutation
HER2 Mutation

Interventions

DRUG: BAY2927088_formulation A
DRUG: BAY2927088_formulation B_1
DRUG: BAY2927088_formulation B_2

Sponsor

Bayer